---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-196961"
form_type: "8-K"
ticker: "ZVRA"
cik: "0001434647"
company_name: "ZEVRA THERAPEUTICS, INC."
filed_at: "2024-08-08T23:59:59+00:00"
generated_at: "2026-05-31T10:48:19.469243+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Zevra Therapeutics Reports Preliminary Q2 2024 Revenue of $4.2-$4.6 Million, Net Loss Widens to $18.9-$19.8 Million

## Summary
- Revenue for Q2 2024 expected between $4.2M and $4.6M, down from $8.47M in Q2 2023 which included a $5.0M milestone payment from AZSTARYS license.
- Net loss for Q2 2024 estimated at $18.9M to $19.8M, compared to a $2.6M net loss in the prior-year quarter.
- Preliminary diluted net loss per share ranges from ($0.47) to ($0.45), versus ($0.08) in Q2 2023.
- Cash and cash equivalents as of June 30, 2024 were approximately $49.3 million.
- The decrease in revenue is partially offset by reimbursements under AZSTARYS License Agreement and increased French expanded access program reimbursements.

## SEC filing metadata
- accession: 0001193125-24-196961
- form_type: 8-K
- ticker: ZVRA
- cik: 0001434647
- company_name: ZEVRA THERAPEUTICS, INC.
- filed_at: 2024-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1434647/000119312524196961/0001193125-24-196961-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1434647/000119312524196961/d881941d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-196961
- JSON: https://secwatch.observer/filing/0001193125-24-196961.json
- Plain text: https://secwatch.observer/filing/0001193125-24-196961.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.